Biotech Startups

Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases. Its lead program, AVC-S-201, is a γδ T cell-targeting antibody being developed for AML and other blood cancers and solid tumors.

5 investors

Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases. The company has three clinical-stage programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.

5 investors

Barnwell Bio runs a biosurveillance platform that analyzes environmental samples such as waste streams to detect pathogen trends and provide animal health data. It serves livestock and poultry producers and veterinarians, offering data to guide disease management and evaluate feed additives, vaccines, and biosecurity protocols.

5 investors

Baseimmune develops active immunotherapies using computational design and protein engineering to create custom antigens aimed at chronic diseases. The company operates in the biotech and therapeutics space.

5 investors

Becoming.bio develops robotic systems that sustain mammalian development outside the body, combining closed-loop hardware for metabolic regulation with AI models that predict how organisms develop and respond to intervention. The company works at the intersection of biology, robotics, and machine learning to study developmental processes and disease.

5 investors

Biodock provides an AI image analysis platform designed for researchers and scientists to train, run, and interpret deep learning models on biological images without requiring coding expertise. The platform enables rapid model creation, distributed execution at scale, and detailed quantitative analysis for research organizations in biotech and life sciences.

5 investors

BioReact provides a data integration platform that unifies experimental data from bioreactors, laboratory instruments, and omics workflows into a standardized, AI-ready format for bioprocess development. The platform serves scientists in synthetic biology, cell therapy, biologics, and precision fermentation who need to consolidate fragmented scientific data for analytics and machine learning.

5 investors

BioRender is a software tool that enables scientists to create and share professional scientific illustrations and figures. The platform serves researchers and scientists across life sciences disciplines globally.

5 investors

Biosapien develops treatments for cancer that are delivered locally to shrink tumors, relieve symptoms, and reduce the need for surgeries.

5 investors

BioStack provides a platform for bioinformatics and experimental science that integrates biological insights with computational technology. The platform serves researchers and scientists working in modern biology and life sciences research.

5 investors

Biostate AI is a biotech company that develops AI-driven solutions for the life sciences and medical research sectors. The company operates multiple international subsidiaries and partnerships focused on advancing genomics and health diagnostics.

5 investors

Biozeroc builds a retrofit reactor architecture for industrial biocatalysis that keeps output steady as enzymes degrade, letting operators maintain specification without replacing their existing enzymes or equipment. It targets high-volume manufacturers running continuous biocatalytic production processes.

5 investors

Blackrock Neurotech develops a neurotechnology platform, including brain-computer interface systems, aimed at improving patient lives and treating neurological conditions. It builds implantable neural interface technology for medical and research applications.

5 investors

BLUU develops marine cell-based ingredients derived from cultured fish cells for personal care, health, and food applications. The company uses proprietary bioprocessing workflows grounded in peer-reviewed research to produce ethically sourced, traceable compounds that replicate results unattainable through land-based agriculture.

5 investors

Bond Pets develops brewed meat proteins using precision fermentation for pet food products that are marketed as better for pets, farm animals, and the planet.

5 investors

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

5 investors

Miist develops inhaled microparticle therapeutics that deliver medicine to the bloodstream in 30 seconds, targeting conditions like migraine, pain, and anxiety where rapid onset is critical. The company is advancing a portfolio of systemic therapies starting with MST-02, a migraine treatment designed to work significantly faster than existing oral medications.

5 investors

Broken String Biosciences develops tools for genome-wide on- and off-target analysis in gene editing, enabling in-house detection and characterization of gene editing-induced DNA breaks. It serves gene editing therapeutic developers working from discovery through IND across diverse cell types and nuclease systems.

5 investors

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.

5 investors

Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy. The medical device is designed to be adaptable to individual patient needs and was developed in collaboration with Mayo Clinic.

5 investors

Caladan Bio develops high-throughput benchtop bioreactor hardware and software for laboratory bioprocessing, enabling faster experimentation and lower costs for biotech R&D teams. The company integrates bioreactor equipment with AI-driven process modeling software to support strain optimization and scale-up workflows.

5 investors

CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. Its drug candidates target conditions such as acute pancreatitis, acute kidney injury, and pulmonary arterial hypertension.

5 investors

CCG.ai develops software for data-driven precision oncology, using clinical and genomic data to identify biomarkers of treatment response and help oncologists choose cancer therapies. It serves clinicians and oncologists in the cancer treatment field.

5 investors

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

5 investors